BR112018069090A2 - tratamento de câncer com base na distribuição de oligos por meio de junções comunicantes a partir de células estaminais mesenquimatosas humanas (hmsc) - Google Patents

tratamento de câncer com base na distribuição de oligos por meio de junções comunicantes a partir de células estaminais mesenquimatosas humanas (hmsc)

Info

Publication number
BR112018069090A2
BR112018069090A2 BR112018069090A BR112018069090A BR112018069090A2 BR 112018069090 A2 BR112018069090 A2 BR 112018069090A2 BR 112018069090 A BR112018069090 A BR 112018069090A BR 112018069090 A BR112018069090 A BR 112018069090A BR 112018069090 A2 BR112018069090 A2 BR 112018069090A2
Authority
BR
Brazil
Prior art keywords
cancer cell
hmsc
stem cells
mesenchymal stem
human mesenchymal
Prior art date
Application number
BR112018069090A
Other languages
English (en)
Inventor
S Cohen Ira
R Rosen Michael
R Brink Peter
Original Assignee
Univ New York State Res Found
Univ Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ New York State Res Found, Univ Columbia filed Critical Univ New York State Res Found
Publication of BR112018069090A2 publication Critical patent/BR112018069090A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Prostheses (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

um método para tratamento de câncer in vivo inclui a introdução in vitro em células estaminais mesenquimatosas humanas (hmscs) de pelo menos um tipo de oligonucleotídeo inibidor e pôr um tecido tumoral de células cancerígenas sinciciais em contato com as hmscs in vivo em condições que permitem que uma hmsc forme um canal de junção comunicante com uma primeira célula cancerígena sincicial do tecido tumoral. como resultado, o pelo menos um tipo de oligonucleotídeo inibidor é distribuído para a primeira célula cancerígena sincicial ao atravessar o canal de junção comunicante e o pelo menos um tipo de oligonucleotídeo inibidor é distribuído para uma segunda célula cancerígena sincicial do tecido tumoral ao atravessar um canal de junção comunicante entre a primeira célula cancerígena sincicial e a segunda célula cancerígena sincicial.
BR112018069090A 2016-03-23 2017-03-23 tratamento de câncer com base na distribuição de oligos por meio de junções comunicantes a partir de células estaminais mesenquimatosas humanas (hmsc) BR112018069090A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662312230P 2016-03-23 2016-03-23
PCT/US2017/023803 WO2017165641A1 (en) 2016-03-23 2017-03-23 CANCER TREATMENT BASED ON DELIVERY OF OLIGOES VIA GAP JUNCTIONS FROM HUMAN MESENCHYMAL STEM CELLS (hMSC)

Publications (1)

Publication Number Publication Date
BR112018069090A2 true BR112018069090A2 (pt) 2019-01-29

Family

ID=59900921

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018069090A BR112018069090A2 (pt) 2016-03-23 2017-03-23 tratamento de câncer com base na distribuição de oligos por meio de junções comunicantes a partir de células estaminais mesenquimatosas humanas (hmsc)

Country Status (10)

Country Link
US (1) US20200171067A1 (pt)
EP (1) EP3432714A4 (pt)
JP (1) JP2019509297A (pt)
KR (1) KR20180123052A (pt)
CN (1) CN108882705A (pt)
AU (2) AU2017238505B2 (pt)
BR (1) BR112018069090A2 (pt)
CA (1) CA3018150A1 (pt)
SG (1) SG11201807223UA (pt)
WO (1) WO2017165641A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL279520B2 (en) 2016-01-15 2023-03-01 American Gene Tech Int Inc Methods and preparations for the activation of gamma-delta t cells
US10137144B2 (en) 2016-01-15 2018-11-27 American Gene Technologies International Inc. Methods and compositions for the activation of gamma-delta T-cells
CN112004923A (zh) * 2017-11-22 2020-11-27 迈索布拉斯特国际有限公司 细胞组合物及治疗方法
KR102145176B1 (ko) * 2017-11-27 2020-08-18 (주)프로스테믹스 올리고뉴클레오티드 및 이를 포함하는 암의 예방 또는 치료용 약학적 조성물
US11352646B2 (en) * 2018-11-05 2022-06-07 American Gene Technologies International Inc. Vector system for expressing regulatory RNA

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050002914A1 (en) * 2003-01-15 2005-01-06 Rosen Michael R. Mesenchymal stem cells as a vehicle for ion channel transfer in syncytial structures
WO2006020322A2 (en) * 2004-07-19 2006-02-23 The Trustees Of Columbia University In The City Of New York Assay system for monitoring the effects of genetically engineered cells to alter function of a syncytium
WO2008141177A1 (en) * 2007-05-11 2008-11-20 The Trustees Of Columbia University In The City Ofnew York Methods and compositions for the treatment of sarcoma
US20090253780A1 (en) * 2008-03-26 2009-10-08 Fumitaka Takeshita COMPOSITIONS AND METHODS RELATED TO miR-16 AND THERAPY OF PROSTATE CANCER

Also Published As

Publication number Publication date
WO2017165641A1 (en) 2017-09-28
CN108882705A (zh) 2018-11-23
AU2021290224A1 (en) 2022-01-20
KR20180123052A (ko) 2018-11-14
SG11201807223UA (en) 2018-09-27
AU2017238505B2 (en) 2021-09-23
EP3432714A1 (en) 2019-01-30
CA3018150A1 (en) 2017-09-28
EP3432714A4 (en) 2019-11-13
AU2017238505A1 (en) 2018-09-06
US20200171067A1 (en) 2020-06-04
JP2019509297A (ja) 2019-04-04

Similar Documents

Publication Publication Date Title
BR112018069090A2 (pt) tratamento de câncer com base na distribuição de oligos por meio de junções comunicantes a partir de células estaminais mesenquimatosas humanas (hmsc)
CO2020015255A2 (es) Métodos y composiciones para tratar el cáncer
WO2019094642A8 (en) T cell manufacturing compositions and methods
BR112012010136A2 (pt) células -tronco pluripotentes
BR112018007538A2 (pt) células exterminadoras naturais e células ilc3 e usos das mesmas
UY35472A (es) Compuestos y sus usos en la modulacion de la hemoglobina
CO6440529A2 (es) Pirimidinonas como inhibidores de pi3k
UY35427A (es) Compuestos y sus usos en la modulación de la hemoglobina
AR100560A1 (es) Inhibición o regulación por disminución de la glucógeno sintasa mediante la creación de codones de terminación prematuros utilizando oligonucléotidos antisentido
DOP2013000240A (es) Composiciones y métodos para transferencia de energía mitocondrial de línea germinal autóloga
UY35425A (es) Compuestos y sus usos en la modulación de la hemoglobina
UY35426A (es) Compuestos y sus usos en la modulación de la hemoglobina
AR090970A1 (es) Diferenciacion de celulas madre humanas embrionarias en endodermo pancreatico
AR118859A1 (es) Composiciones y métodos de fabricación de células t
BR112018007174A2 (pt) instrumento para higiene bucal com saliências condutoras
NZ630598A (en) Method of engrafting cells from solid tissues
MX2020011415A (es) Metodos de usar zscan4 para rejuvenecer celulas humanas.
GEP20166449B (en) Treatment of pain associated with dislocation of basal endometrium
AR080722A2 (es) Metodo para regular la expresion de un blanco con una construccion de nucleotidos y para tratar un acondicion patologica
BR112018070293A2 (pt) diferenciação de células-tronco pluripotentes em células do endoderma intestinal do intestino médio
MX2020011254A (es) Celulas t car anti-bcma para agotamiento de celulas de plasma.
MX2016004616A (es) Parches de células musculares y usos de los mismos.
GB2539858A (en) Vaginal insert
BR112017019189A2 (pt) agente terapêutico celular para tratamento de câncer e terapia de combinação com o mesmo
BR112018008931A2 (pt) ?compostos para tratamento de distúrbios hipoproliferativos?

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: AS CLASSIFICACOES ANTERIORES ERAM: A01N 43/04 , A61N 1/362 , A61P 35/00 , C07H 21/00 , C07H 21/04 , C12P 19/34

Ipc: A61K 31/7105 (2006.01), A61K 31/713 (2006.01), A61

B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements